BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang MY, Fang WY, Lee SC, Cheng TL, Wang JY, Lin SR. ERCC2 2251A& gt; C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. BMC Cancer. 2008;8:50. [PMID: 18267032 DOI: 10.1186/1471-2407-8-50] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Choi R, Lee MN, Kim K, Baek SY, Kim TJ, Hong SN, Kim YH, Lee SY. Effects of various genetic polymorphisms on thiopurine treatment-associated outcomes for Korean patients with Crohn's disease. Br J Clin Pharmacol 2020;86:2302-13. [PMID: 32372428 DOI: 10.1111/bcp.14339] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Olivera G, Sendra L, Herrero MJ, Puig C, Aliño SF. Colorectal cancer: pharmacogenetics support for the correct drug prescription. Pharmacogenomics 2019;20:741-63. [PMID: 31368847 DOI: 10.2217/pgs-2019-0041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Choi R, Sohn I, Kim MJ, Woo HI, Lee JW, Ma Y, Yi ES, Koo HH, Lee SY. Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia. Br J Clin Pharmacol 2019;85:1585-97. [PMID: 30927276 DOI: 10.1111/bcp.13943] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
4 Liu D, Li X, Li X, Zhang M, Zhang J, Hou D, Tong Z, Dong M. CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy. Cancer Chemother Pharmacol 2019;83:939-49. [DOI: 10.1007/s00280-019-03809-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 ElHarouni D, Yassin D, Ali N, Gohar S, Zaky I, Adwan H, Sidhom I. A Pharmacogenetic Study of VDR fok1 and TYMS Polymorphisms and Their Association With Glucocorticoid-Induced Osteonecrosis in Egyptian Children With Acute Lymphoblastic Leukemia. Front Oncol 2018;8:541. [PMID: 30533396 DOI: 10.3389/fonc.2018.00541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
6 Castro-Rojas CA, Esparza-Mota AR, Hernandez-Cabrera F, Romero-Diaz VJ, Gonzalez-Guerrero JF, Maldonado-Garza H, Garcia-Gonzalez IS, Buenaventura-Cisneros S, Sanchez-Lopez JY, Ortiz-Lopez R, Camacho-Morales A, Barboza-Quintana O, Rojas-Martinez A. Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer. Drug Metab Pers Ther 2017;32:209-18. [PMID: 29257755 DOI: 10.1515/dmpt-2017-0028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
7 Zhong L, He X, Zhang Y, Chuan JL, Chen M, Zhu SM, Peng Q. Relevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidine-based chemotherapy in colorectal cancer: a systematic review and meta-analysis. Oncotarget 2018;9:31291-301. [PMID: 30131855 DOI: 10.18632/oncotarget.24933] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
8 Huang MY, Huang JJ, Huang CM, Lin CH, Tsai HL, Huang CW, Chai CY, Lin CY, Wang JY. Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy. World J Surg 2017;41:2884-97. [PMID: 28608017 DOI: 10.1007/s00268-017-4070-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wang M, Li Q, Gu C, Zhu Y, Yang Y, Wang J, Jin L, He J, Ye D, Wei Q. Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations. Oncotarget 2017;8:24362-71. [PMID: 27974699 DOI: 10.18632/oncotarget.13848] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
10 Liu J, Li H, Sun L, Feng X, Wang Z, Yuan Y, Xing C. The Differential Expression of Core Genes in Nucleotide Excision Repair Pathway Indicates Colorectal Carcinogenesis and Prognosis. Biomed Res Int 2018;2018:9651320. [PMID: 29568775 DOI: 10.1155/2018/9651320] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
11 Huang CW, Chen YT, Tsai HL, Yeh YS, Su WC, Ma CJ, Tsai TN, Wang JY. EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function. Oncotarget 2017;8:114663-76. [PMID: 29383110 DOI: 10.18632/oncotarget.23072] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
12 Yeh C, Lai C, Chang S, Hsieh L, Tang R, Sung F, Lin Y. Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. Int J Clin Oncol 2017;22:484-93. [DOI: 10.1007/s10147-016-1080-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
13 Kap EJ, Popanda O, Chang-claude J. Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients. Pharmacogenomics 2016;17:755-94. [DOI: 10.2217/pgs-2015-0017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
14 Lee MN, Kang B, Choi SY, Kim MJ, Woo SY, Kim JW, Choe YH, Lee SY. Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine. Inflamm Bowel Dis 2015;21:2897-908. [PMID: 26332308 DOI: 10.1097/MIB.0000000000000570] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
15 Gómez-Díaz B, DE LA Luz Ayala-Madrigal M, Gutiérrez-Angulo M, Valle-Solis AE, Linares-González LM, González-Guzmán R, Cruz-Guillén D, Cedeño-Garcidueñas AL, Canto P, López-Hernández LB. Analysis of ERCC1 and ERCC2 gene variants in osteosarcoma, colorectal and breast cancer. Oncol Lett 2015;9:1657-61. [PMID: 25789018 DOI: 10.3892/ol.2015.2894] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
16 Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC. Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. PLoS One 2014;9:e107424. [PMID: 25232828 DOI: 10.1371/journal.pone.0107424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Mohelnikova-Duchonova B, Melichar B, Soucek P. FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World J Gastroenterol 2014; 20(30): 10316-10330 [PMID: 25132748 DOI: 10.3748/wjg.v20.i30.10316] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
18 Sebio A, Lenz H. Clinical importance of recently discovered gene variants in colon cancer recurrence and prognosis. Colorectal Cancer 2014;3:147-162. [DOI: 10.2217/crc.14.2] [Reference Citation Analysis]
19 Ni M, Zhang WZ, Qiu JR, Liu F, Li M, Zhang YJ, Liu Q, Bai J. Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population. Sci Rep 2014;4:4112. [PMID: 24531312 DOI: 10.1038/srep04112] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
20 Chen TH, Chang SW, Huang CC, Wang KL, Yeh KT, Liu CN, Lee H, Lin CC, Cheng YW. The prognostic significance of APC gene mutation and miR-21 expression in advanced-stage colorectal cancer. Colorectal Dis 2013;15:1367-74. [PMID: 23773491 DOI: 10.1111/codi.12318] [Cited by in Crossref: 46] [Cited by in F6Publishing: 55] [Article Influence: 4.6] [Reference Citation Analysis]
21 Huang MY, Tsai HL, Lin CH, Huang CW, Ma CJ, Huang CM, Chai CY, Wang JY. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy. J Surg Oncol. 2013;108:457-464. [PMID: 23996617 DOI: 10.1002/jso.23422] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
22 Woo HI, Kim KK, Choi H, Kim S, Jang KT, Yi JH, Park YS, Park JO, Lee SY. Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine. Pharmacogenomics 2012;13:1023-35. [PMID: 22838950 DOI: 10.2217/pgs.12.82] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
23 Huang MY, Wang JY, Huang ML, Chang HJ, Lin SR. Polymorphisms in XPD and ERCC1 Associated with Colorectal Cancer Outcome. Int J Mol Sci 2013;14:4121-34. [PMID: 23429196 DOI: 10.3390/ijms14024121] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
24 Kim H, Kang HJ, Kim HJ, Jang MK, Kim NH, Oh Y, Han BD, Choi JY, Kim CW, Lee JW, Park KD, Shin HY, Ahn HS. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS One 2012;7:e45558. [PMID: 23029095 DOI: 10.1371/journal.pone.0045558] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
25 Jennings BA, Kwok CS, Willis G, Matthews V, Wawruch P, Loke YK. Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet Genomics. 2012;22:290-304. [PMID: 22388795 DOI: 10.1097/fpc.0b013e328351875d] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
26 Fariña Sarasqueta A, van Lijnschoten G, Lemmens VE, Rutten HJ, van den Brule AJ. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers? Mol Diagn Ther 2011;15:277-83. [PMID: 21958378 DOI: 10.1007/BF03256419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
27 Fariña Sarasqueta A, van Lijnschoten G, Lemmens VE, Rutten HJ, van den Brule AJ. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers? Mol Diagn Ther 2011;15:277-83. [PMID: 21958378 DOI: 10.1007/BF03256419] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Valachis A, Mauri D, Neophytou C, Polyzos NP, Tsali L, Garras A, Papanikolau EG. Translational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not? Int J Med Sci 2011;8:492-500. [PMID: 21897762 DOI: 10.7150/ijms.8.492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
29 Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics. 2011;21:237-242. [PMID: 20601926 DOI: 10.1097/fpc.0b013e32833c6107] [Cited by in Crossref: 56] [Cited by in F6Publishing: 69] [Article Influence: 4.7] [Reference Citation Analysis]
30 Soltysova A, Minarik G, Dzurenkova A, Sufliarska S, Kadasi L, Turna J, Mladosievicova B. APEX microarray panel for genotyping polymorphisms in cancer chemotherapy and estimation frequencies in a Slovak population. Pharmacogenomics 2011;12:577-592. [DOI: 10.2217/pgs.10.199] [Reference Citation Analysis]
31 Gonzalez-haba E, García MI, Cortejoso L, López-lillo C, Barrueco N, García-alfonso P, Alvarez S, Jiménez JL, Martín ML, Muñóz-fernández MA, Sanjurjo M, López-fernández LA. ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics 2010;11:1715-23. [DOI: 10.2217/pgs.10.159] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
32 Hwang CC, Chai HT, Chen HW, Tsai HL, Lu CY, Yu FJ, Huang MY, Wang JY. S100B protein expressions as an independent predictor of early relapse in UICC stages II and III colon cancer patients after curative resection. Ann Surg Oncol 2011;18:139-45. [PMID: 20628824 DOI: 10.1245/s10434-010-1209-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
33 Schwarzenbach H. Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy. EPMA J 2010;1:485-94. [PMID: 23199090 DOI: 10.1007/s13167-010-0022-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
34 Zintzaras E, Ziogas DC, Kitsios GD, Papathanasiou AA, Lau J, Raman G. MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. Pharmacogenomics. 2009;10:1285-1294. [PMID: 19663673 DOI: 10.2217/pgs.09.59] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
35 Tsai HL, Chu KS, Huang YH, Su YC, Wu JY, Kuo CH, Chen CW, Wang JY. Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol 2009;100:736-43. [PMID: 19757443 DOI: 10.1002/jso.21404] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 4.9] [Reference Citation Analysis]
36 Chang HJ, Huang MY, Yeh CS, Chen CC, Yang MJ, Sun CS, Lee CK, Lin SR. Rapid diagnosis of tuberculosis directly from clinical specimens using a gene chip. Clin Microbiol Infect 2010;16:1090-6. [PMID: 19732084 DOI: 10.1111/j.1469-0691.2009.03045.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
37 Le H, Ziogas A, Taylor TH, Lipkin SM, Zell JA. Survival of distinct Asian groups among colorectal cancer cases in California. Cancer 2009;115:259-70. [PMID: 19109815 DOI: 10.1002/cncr.24034] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]